Evidence, explained.
Clear, clinically grounded answers to the questions men actually ask about testosterone, peptides, GLP-1s, and longevity — written by the provider you'd see in clinic.
Peptides and the FDA: Where Things Actually Stand in 2026
Most longevity peptides sit in a legal gray zone right now, and an FDA meeting later this month could change that. What's restricted, what's under review, and what we can actually prescribe.
Read articlePDE5 Inhibitors: From the Bedroom to the Longevity Conversation
What the data actually says about sildenafil, tadalafil, and the link to lower all-cause mortality, cardiovascular events, and dementia risk.
Read articleTirzepatide: the trials, the class, and the microdose question.
A walk through SURMOUNT and SURPASS, how tirzepatide stacks up against semaglutide, what microdosing actually means, and who benefits — beyond just BMI.
Read articleEnclomiphene vs. TRT: Which should you try first?
A provider's honest comparison of enclomiphene and testosterone replacement therapy — fertility, the HPG axis, cost, and who's a candidate for each.
Read articleDoes TRT cause blood clots? What the TRAVERSE trial actually found.
A plain-English walkthrough of the largest randomized trial on testosterone therapy and cardiovascular safety — and what the clotting signal really means for men starting treatment.
Read article